BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The applicant Genetics Institute of Europe B.V. (Germany) submitted on 9 March 2001 an application 
for  Marketing  Authorisation  to  the  European  Agency  for  the  Evaluation  of  Medicinal  Products 
(EMEA) for InductOs, in accordance with the centralised procedure falling within the scope of Part A 
of the Annex to Council Regulation No (EEC) 2309/93 of 22 July 1993. 
The Rapporteur and Co-Rapporteur appointed by the CPMP were: 
Rapporteur:  Dr. Barbara van Zwieten-Boot   
Co-Rapporteur:  Dr. Markku Toivonen 
Licensing status: 
The product was not licensed in any country at the time of submission of the application. 
2. 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
Steps taken for the assessment of the product 
The procedure started on 16 March 2001. 
The  Rapporteur's  first  Assessment  Report  was  circulated  to  all  CPMP  members  on  
12  June  2001.  The  Co-Rapporteur's  first  Assessment  Report  was  circulated  to  all  CPMP 
members on 4 June 2001. 
During the meeting on 24-26 July 2001 the CPMP agreed on the consolidated List of Questions 
to be sent to the applicant. The final consolidated List of Questions was sent to the applicant on 
26 July 2001. 
The  company  submitted  the  responses  to  the  CPMP  consolidated  List  of  Questions  on  
13 November 2001. 
The  summary  report  of  the  inspection  carried  out  at  the  Integra  LifeSciences  Corporation 
manufacturing 
sponge)  between  
the 
22-24 January 2002, and of 10-11 April 2002 (follow-up inspection) by the MCA was issued on 
10 May 2002. 
(manufacturer  of 
absorbable 
collagen 
site 
The Rapporteur circulated the response Assessment Report on the company’s responses to the 
List of Questions to all CPMP members on 15 January 2002. 
During the meeting on 11-13 February 2002, the BWP discussed the outstanding quality issues. 
A report to the CPMP was prepared. 
During the CPMP meeting on 19-21 February 2002 the CPMP adopted a list of questions to be 
addressed during an oral explanation. 
During the CPMP meeting of 23-25 April 2002, the CPMP agreed that there was no need for an 
oral explanation. A list of outstanding issues to be addressed in writing prior to the opinion was 
issued.  
The  company  submitted  answers  to  the  outstanding  quality  questions  on  18  April  2002.  The 
Rapporteur circulated an assessment report of these answers to all CPMP members on 17 May 
2002. 
The company submitted written responses to the Part IV-Clinical/SPC issues on 22 May 2002. 
During  the  meeting  on  21-23  May  2002  the  BWP  discussed  the  responses  on  the  outstanding 
quality questions, and prepared a final report to the CPMP. 
During the meeting on 28-30 May 2002 the CPMP, in the light of the overall data submitted and 
the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a 
Marketing Authorisation to InductOs on 30 May 2002. 
The  CPMP  opinions  were  forwarded,  in  all  official  languages  of  the  European  Union,  to  the 
European Commission, which adopted the corresponding Decisions on 9 September 2002. 
1/1 
EMEA 2004 
 
 
